Adjuvant platinum-based chemotherapy has been the main treatment following surgical resection with curative intent in early and locally advanced nonsmall cell lung cancer (NSCLC) albeit with a 5% improvement in 5-year survival rates. Recent advances in biomarkers pave the way for targeted treatments and immunotherapy in a broader spectrum of patients with subsequently improved clinical outcomes. Targeted treatments and immunotherapy have established their place in the adjuvant setting of resected NSCLC.
Keyphrases
- locally advanced
- rectal cancer
- squamous cell carcinoma
- neoadjuvant chemotherapy
- early stage
- small cell lung cancer
- phase ii study
- radiation therapy
- cancer therapy
- advanced non small cell lung cancer
- stem cells
- combination therapy
- mesenchymal stem cells
- cell therapy
- prognostic factors
- epidermal growth factor receptor
- bone marrow